3D Immersive Website Platform, Peach Worlds, Secures Pre-Seed Funding to Transform Online Experiences
LONDON, Dec. 20, 2023 /PRNewswire/ — Peach Worlds, the Squarespace for 3D Immersive Websites, recently secured a pre-seed investment of USD$540,000. Blockchain Founders Fund co-invested in this round alongside former Multimedia Director of Apple, Antonio Rallo’s ID345 fund and several a
Boomerang Ventures Leads $1.7M Series Seed Round for Pediatric Digital Health Startup Xploro Inc.
INDIANAPOLIS, Dec. 20, 2023 /PRNewswire/ — Boomerang Ventures, a leading venture capital and studio firm, has strategically invested in Xploro Inc., a pioneer in pediatric digital health. Leading the $1.7M Series Seed round, Boomerang Ventures underscores its dedication to fostering innovation
" title="Centering Disability Within DEI, Nonprofit AHRC Nassau Named to Forbes “America’s Best-In-State Employers” List; Tapped by NY State to Offer DEI Training in Multi-Year Grant
BROOKVILLE, N.Y., Dec. 20, 2023 /PRNewswire/ — As a CQL with Distinction and Compass agency, AHRC Nassau has long been recognized for providing the highest-quality disability supports to Long Islanders with developmental disabilities. Now, AHRC has been named one of “America’s
Qatar-Indonesia 2023 Year of Culture Wraps Up, Leaves Lasting Legacy of Cooperation Across Travel, Tourism and Creative Industries
DOHA, Qatar, and JAKARTA, Indonesia, Dec. 20, 2023 /PRNewswire/ — The Qatar–Indonesia 2023 Year of Culture will soon come to an end, leaving an indelible mark on the cultural landscape of both nations. A joint 12-month endeavor, the Year of Culture sought to deepen the understanding of
Complex Litigation Law Firm Berger Montague Ends Year of Monumental Growth with the Appointment of Two New Shareholders: Alexandra K. Piazza and Yechiel Michael Twersky
Following their decade-plus of service to Berger Montague, Ms. Piazza and Mr. Twersky are Named Firm Shareholders PHILADELPHIA, Dec. 20, 2023 /PRNewswire/ — Complex litigation powerhouse Berger Montague is pleased to announce that the Firm has appointed two new shareholders, effective Janua
NovoEd Recognized as an Industry-Defining Learning Solution Provider in the Brandon Hall Group’s 2023 Technology and EdTech Excellence Awards
Cohort Learning Platform Honored with 29 Medals — One of the Programs’ Most Highly Awarded Organizations — for Its Innovations in Education Technology, Learning & Development, Workforce Management, the Future of Work, and More SAN FRANCISCO, Dec. 20, 2023 /PRNewswire/ — With hon
Skanska divests the office building 9000 Wilshire in Beverly Hills, California, USA, for about USD 71M, about SEK 750M
STOCKHOLM, Dec. 20, 2023 /PRNewswire/ — Skanska divests the office building 9000 Wilshire in Beverly Hills, California, to a company based in Europe for about USD 71M, about SEK 750M. The transaction will be recorded by Skanska USA Commercial Development in the fourth quarter 2023. The buyer w
Chestnut Carbon to Deliver High-Quality Carbon Removal Credits through a Multi-year Offtake Agreement with Microsoft
Chestnut will Remove 362,000 Tons of Carbon for Microsoft in Phase I of the Largest U.S. Gold Standard-Registered Afforestation Project NEW YORK, Dec. 20, 2023 /PRNewswire/ — Chestnut Carbon (“Chestnut”), a nature-based carbon removal developer founded by private investment firm Ki
John Hancock Investment Management Launches New Active International Equity ETF Subadvised by Boston Partners
BOSTON, Dec. 20, 2023 /PRNewswire/ – John Hancock Investment Management, a company of Manulife Investment Management, today will launch John Hancock Disciplined Value International Select ETF (NYSE Arca: JDVI). The new fund seeks long-term capital growth and is managed by a veteran team at
CellVax Submits IND Application for Individualized Cell-based Immunotherapy FK-PC101 with Support of Theragent
ARCADIA, Calif., Dec. 20, 2023 /PRNewswire/ — Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapies, announced that their sponsor client, CellVax Therapeutics Inc., has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug
